The role of cytokines in pediatric hematologic malignancies: mechanisms of tumor progression and therapeutic implications - a narrative review.

IF 1.6 Q2 MEDICINE, GENERAL & INTERNAL
Annals of Medicine and Surgery Pub Date : 2025-05-21 eCollection Date: 2025-06-01 DOI:10.1097/MS9.0000000000003295
Emmanuel Ifeanyi Obeagu
{"title":"The role of cytokines in pediatric hematologic malignancies: mechanisms of tumor progression and therapeutic implications - a narrative review.","authors":"Emmanuel Ifeanyi Obeagu","doi":"10.1097/MS9.0000000000003295","DOIUrl":null,"url":null,"abstract":"<p><p>Cytokines play a pivotal role in the progression and pathogenesis of pediatric hematologic malignancies, such as leukemia and lymphoma, by orchestrating the tumor microenvironment (TME). These soluble signaling molecules regulate key processes, including immune modulation, tumor cell proliferation, angiogenesis, and resistance to therapy. Elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) promote survival pathways, chemoresistance, and immune evasion, while anti-inflammatory cytokines like IL-10 further suppress effective anti-tumor immunity. Targeting cytokine signaling pathways has emerged as a promising therapeutic strategy. Advances in monoclonal antibody therapies, signal transduction inhibitors, and cytokine-neutralizing agents aim to disrupt the pro-tumorigenic effects of cytokines within the TME. Additionally, integrating cytokine modulation with immune checkpoint inhibitors and adoptive cell therapy enhances anti-tumor immune responses. These approaches are complemented by novel therapeutics designed to mitigate resistance to conventional treatments, such as chemotherapies, which are often driven by persistent cytokine-mediated signaling.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"87 6","pages":"3551-3555"},"PeriodicalIF":1.6000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140796/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine and Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/MS9.0000000000003295","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Cytokines play a pivotal role in the progression and pathogenesis of pediatric hematologic malignancies, such as leukemia and lymphoma, by orchestrating the tumor microenvironment (TME). These soluble signaling molecules regulate key processes, including immune modulation, tumor cell proliferation, angiogenesis, and resistance to therapy. Elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) promote survival pathways, chemoresistance, and immune evasion, while anti-inflammatory cytokines like IL-10 further suppress effective anti-tumor immunity. Targeting cytokine signaling pathways has emerged as a promising therapeutic strategy. Advances in monoclonal antibody therapies, signal transduction inhibitors, and cytokine-neutralizing agents aim to disrupt the pro-tumorigenic effects of cytokines within the TME. Additionally, integrating cytokine modulation with immune checkpoint inhibitors and adoptive cell therapy enhances anti-tumor immune responses. These approaches are complemented by novel therapeutics designed to mitigate resistance to conventional treatments, such as chemotherapies, which are often driven by persistent cytokine-mediated signaling.

细胞因子在儿童血液恶性肿瘤中的作用:肿瘤进展和治疗意义的机制-叙述回顾。
细胞因子通过调控肿瘤微环境(TME)在儿童血液恶性肿瘤(如白血病和淋巴瘤)的进展和发病机制中发挥关键作用。这些可溶性信号分子调节关键过程,包括免疫调节、肿瘤细胞增殖、血管生成和对治疗的抵抗。白细胞介素-6 (IL-6)和肿瘤坏死因子-α (TNF-α)等促炎细胞因子水平的升高促进了生存途径、化疗耐药和免疫逃避,而IL-10等抗炎细胞因子进一步抑制了有效的抗肿瘤免疫。靶向细胞因子信号通路已成为一种有前景的治疗策略。单克隆抗体疗法、信号转导抑制剂和细胞因子中和剂的进展旨在破坏细胞因子在TME中的促肿瘤作用。此外,整合细胞因子调节与免疫检查点抑制剂和过继细胞治疗增强抗肿瘤免疫应答。这些方法的补充是新的治疗方法,旨在减轻对常规治疗的耐药性,如化疗,这通常是由持续的细胞因子介导的信号驱动的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Medicine and Surgery
Annals of Medicine and Surgery MEDICINE, GENERAL & INTERNAL-
自引率
5.90%
发文量
1665
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信